BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12

American Journal of Transplantation

Volumn 16, Issue 3, 2016, Pages 821-832

  Hirsch, H H ^a,b   Yakhontova, K ^a   Lu, M ^a   Manzetti, J ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CYCLOSPORIN A; FK BINDING PROTEIN 12; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOTRANSFERASE; RAPAMYCIN; SMALL INTERFERING RNA; SP6 KINASE; TACROLIMUS; UNCLASSIFIED DRUG; FK 506 BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA;

ARTICLE; BK VIRUS; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY TUBULE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECTS; EPITHELIUM CELL; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; INFANT; KIDNEY TUBULE; METABOLISM; PHYSIOLOGY; POLYOMAVIRUS INFECTIONS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VIRUS INFECTIONS; VIROLOGY; WESTERN BLOTTING;

BK VIRUS; BLOTTING, WESTERN; CELLS, CULTURED; EPITHELIAL CELLS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TUBULES; POLYOMAVIRUS INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIROLIMUS; TACROLIMUS; TACROLIMUS BINDING PROTEIN 1A; TUMOR VIRUS INFECTIONS; VIRUS REPLICATION;

EID: 84959268501     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13541     Document Type: Article

References (61)

1. Fishman JA., BK virus nephropathy-Polyomavirus adding insult to injury. N Engl J Med 2002; 347: 527-530.
2. Ramos E, Drachenberg CB, Wali R, Hirsch HH., The decade of polyomavirus BK-associated nephropathy: State of affairs. Transplantation 2009; 87: 621-630.
3. Kuypers DR., Management of polyomavirus-associated nephropathy in renal transplant recipients. Nat Rev Nephrol 2012; 8: 390-402.
4. Elfadawy N, Flechner SM, Schold JD, et al., Transient versus persistent BK viremia and long-term outcomes after kidney and kidney-pancreas transplantation. Clin J Am Soc Nephrol 2014; 9: 553-561.
5. Hirsch HH, Knowles W, Dickenmann M, et al., Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347: 488-496.
6. Hirsch HH, Brennan DC, Drachenberg CB, et al., Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277-1286.
7. Kasiske BL, Zeier MG, Chapman JR, et al., KDIGO clinical practice guideline for the care of kidney transplant recipients: A summary. Kidney Int 2010; 77: 299-311.
8. Hirsch HH, Randhawa P., BK polyomavirus in solid organ transplantation. Am J Transplant 2013; (13 Suppl 4): 179-188.
9. Brennan DC, Agha I, Bohl DL, et al., Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5: 582-594.
10. Ginevri F, Azzi A, Hirsch HH, et al., Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007; 7: 2727-2735.
11. Binggeli S, Egli A, Schaub S, et al., Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant 2007; 7: 1131-1139.
12. Schaub S, Hirsch HH, Dickenmann M, et al., Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant 2010; 10: 2615-2623.
13. Sood P, Senanayake S, Sujeet K, et al., Management and outcome of BK viremia in renal transplant recipients: A prospective single-center study. Transplantation 2012; 94: 814-821.
14. Huang G, Wang CX, Zhang L, et al., Monitoring of polyomavirus BK replication and impact of preemptive immunosuppression reduction in renal-transplant recipients in China: A 5-year single-center analysis. Diagn Microbiol Infect Dis 2015; 81: 21-26.
15. Drachenberg CB, Papadimitriou JC, Wali R, et al., Improved outcome of polyoma virus allograft nephropathy with early biopsy. Transplant Proc 2004; 36: 758-759.
16. Gosert R, Rinaldo CH, Funk GA, et al., Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med 2008; 205: 841-852.
17. Ramos E, Drachenberg CB, Papadimitriou JC, et al., Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13: 2145-2151.
18. Khamash HA, Wadei HM, Mahale AS, et al., Polyomavirus-associated nephropathy risk in kidney transplants: The influence of recipient age and donor gender. Kidney Int 2007; 71: 1302-1309.
19. Comoli P, Azzi A, Maccario R, et al., Polyomavirus BK-specific immunity after kidney transplantation. Transplantation 2004; 78: 1229-1232.
20. Bohl DL, Storch GA, Ryschkewitsch C, et al., Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant 2005; 5: 2213-2221.
21. Schold JD, Rehman S, Kayler LK, Magliocca J, Srinivas TR, Meier-Kriesche HU., Treatment for BK virus: Incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 2009; 22: 626-634.
22. Dharnidharka VR, Cherikh WS, Abbott KC., An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009; 87: 1019-1026.
23. Borni-Duval C, Caillard S, Olagne J, et al., Risk factors for BK virus infection in the era of therapeutic drug monitoring. Transplantation 2013; 95: 1498-1505.
24. Hirsch HH, Vincenti F, Friman S, et al., Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: A prospective, randomized, multicenter study. Am J Transplant 2013; 13: 136-145.
25. Elfadawy N, Flechner SM, Liu X, et al., The impact of surveillance and rapid reduction in immunosuppression to control BK virus-related graft injury in kidney transplantation. Transpl Int 2013; 26: 822-832.
26. Mackenzie EF, Poulding JM, Harrison PR, Amer B., Human polyoma virus (HPV)-A significant pathogen in renal transplantation. Proc Eur Dial Transplant Assoc 1978; 15: 352-360.
27. Hirsch HH., Polyomavirus BK nephropathy: A (re-)emerging complication in renal transplantation. Am J Transplant 2002; 2: 25-30.
28. Purighalla R, Shapiro R, McCauley J, Randhawa P., BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis 1995; 26: 671-673.
29. Randhawa PS, Finkelstein S, Scantlebury V, et al., Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999; 67: 103-109.
30. Binet I, Nickeleit V, Hirsch HH, et al., Polyomavirus disease under new immunosuppressive drugs: A cause of renal graft dysfunction and graft loss. Transplantation 1999; 67: 918-922.
31. Drachenberg CB, Beskow CO, Cangro CB, et al., Human polyoma virus in renal allograft biopsies: Morphological findings and correlation with urine cytology. Hum Pathol 1999; 30: 970-907.
32. Howell DN, Smith SR, Butterly DW, et al., Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation 1999; 68: 1279-1288.
33. Vincenti F, Friman S, Scheuermann E, et al., Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506-1514.
34. Tedesco Silva H Jr, Cibrik D, Johnston T, et al., Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10: 1401-1413.
35. Hodur DM, Mandelbrot D., Immunosuppression and BKV Nephropathy. N Engl J Med 2002; 347: 2079-2080; author reply 2080.
36. Dharnidharka VR, Abdulnour HA, Araya CE., The BK virus in renal transplant recipients-Review of pathogenesis, diagnosis, and treatment. Pediatr Nephrol 2011; 26: 1763-1774.
37. Hirsch HH, Steiger J, Mihatsch MJ., Immunosuppression and BKV nephropathy. N Engl J Med 2002; 347: 2079-2080.
38. Rinaldo CH, Gosert R, Bernhoff E, Finstad S, Hirsch HH., 1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells. Antimicrob Agents Chemother 2010; 54: 4714-4722.
39. Bernhoff E, Gutteberg TJ, Sandvik K, Hirsch HH, Rinaldo CH., Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am J Transplant 2008; 8: 1413-1422.
40. Kardas P, Sadeghi M, Weissbach FH, et al., Inter- and intralaboratory comparison of JC polyomavirus antibody testing using two different virus-like particle-based assays. Clin Vaccine Immunol 2014; 21: 1581-1588.
41. Simon-Santamaria J, Rinaldo CH, Kardas P, et al., Efficient uptake of blood-borne BK and JC polyomavirus-like particles in endothelial cells of liver sinusoids and renal vasa recta. PLoS One 2014; 9: e111762.
42. Rinaldo CH, Traavik T, Hey A., The agnogene of the human polyomavirus BK is expressed. J Virol 1998; 72: 6233-6236.
43. Dumoulin A, Hirsch HH., Reevaluating and optimizing polyomavirus BK and JC real-time PCR assays to detect rare sequence polymorphisms. J Clin Microbiol 2011; 49: 1382-1388.
44. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM., A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012; 485: 109-113.
45. Thoreen CC, Kang SA, Chang JW, et al., An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284: 8023-8032.
46. Chung J, Kuo CJ, Crabtree GR, Blenis J., Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992; 69: 1227-1236.
47. Hara K, Yonezawa K, Kozlowski MT, et al., Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 1997; 272: 26457-26463.
48. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP., mTOR kinase structure, mechanism and regulation. Nature 2013; 497: 217-223.
49. Funk GA, Gosert R, Comoli P, Ginevri F, Hirsch HH., Polyomavirus BK replication dynamics in vivo and in silico to predict cytopathology and viral clearance in kidney transplants. Am J Transplant 2008; 8: 2368-2377.
50. Liacini A, Seamone ME, Muruve DA, Tibbles LA., Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: Toward a new therapy for BK virus infection. Transplantation 2010; 90: 1450-1457.
51. Groth CG, Backman L, Morales JM, et al., Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-1042.
52. Kahan BD, Napoli KL, Kelly PA, et al., Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity. Clin Transplant 2000; 14: 97-109.
53. Cattaneo D, Merlini S, Pellegrino M, et al., Therapeutic drug monitoring of sirolimus: Effect of concomitant immunosuppressive therapy and optimization of drug dosing. Am J Transplant 2004; 4: 1345-1351.
54. Zoncu R, Efeyan A, Sabatini DM., mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
55. Campistol JM, Eris J, Oberbauer R, et al., Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-589.
56. Gardner SD, Field AM, Coleman DV, Hulme B., New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1971; 1: 1253-1257.
57. Li YJ, Wu HH, Weng CH, et al., Cyclophilin A and nuclear factor of activated T cells are essential in cyclosporine-mediated suppression of polyomavirus BK replication. Am J Transplant 2012; 12: 2348-2362.
58. Li YJ, Weng CH, Lai WC, et al., A suppressive effect of cyclosporine A on replication and noncoding control region activation of polyomavirus BK virus. Transplantation 2010; 89: 299-306.
59. Acott PD, O'Regan PA, Lee SH, Crocker JF., In vitro effect of cyclosporin A on primary and chronic BK polyoma virus infection in Vero E6 cells. Transpl Infect Dis 2008; 10: 385-390.
60. Egli A, Dumoulin A, Köhli S, Hirsch HH., Polyomavirus BK after kidney transplantation-Role of molecular and immunological markers. Trends Transplant 2009; 3: 85-102.
61. Acott P, O'Regan PA, Crocker JF., Suppression of early and chronic BK polyoma virus replication by mycophenolic acid in Vero cells. Transpl Int 2009; 22: 225-231.